Metsera, Inc. Common Stock (MTSR NASDAQ) stock market data APIs
$69.8104
0(0%)
as of November 14, 2025
Try our APIs with
free plan!
Metsera, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.
Prev. Close
69.8104
Open
69.8104
High
69.8104
Low
69.8104
52 wk Range
12.3-83.86
Market Cap
7 429 M
Shares Outstanding
105 M
EPS
-1.11
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Metsera, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Metsera, Inc. Common Stock data using free add-ons & libraries
Get Metsera, Inc. Common Stock Fundamental Data
Metsera, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -265 120 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-30
- EPS/Forecast: -0.675
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Metsera, Inc. Common Stock News
New
Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating
Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy...
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized...
Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) walked into Monday hoping for a spark. Instead, it stepped into a crater of its own making. The company revealed that its pill versio...
PFE- The Winner in the Metsera Bidding War
Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to b...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
